Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1403752/000119312519065609/d662324d10k.htm
SEC Filings
ZYME Annual Reports
ZYME Quarterly Reports
10-Q Quarterly Report August 2022
10-Q Quarterly Report May 2022
10-Q Quarterly Report November 2021
10-Q Quarterly Report August 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report November 2020
10-Q Quarterly Report August 2020
10-Q Quarterly Report May 2020
10-Q Quarterly Report November 2019
10-Q Quarterly Report August 2019
10-Q Quarterly Report August 2022
10-Q Quarterly Report May 2022
10-Q Quarterly Report November 2021
10-Q Quarterly Report August 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report November 2020
10-Q Quarterly Report August 2020
10-Q Quarterly Report May 2020
10-Q Quarterly Report November 2019
10-Q Quarterly Report August 2019
ZYME Corporate News
Other Events August 2022
Event for Officers
Financial Exhibit
Regulated Disclosure August 2022
Earnings Release
Financial Exhibit August 2022
Financial Exhibit
Regulated Disclosure August 2022
Financial Exhibit
Regulated Disclosure July 2022
Financial Exhibit
Regulated Disclosure July 2022
Financial Exhibit
Regulated Disclosure July 2022
Financial Exhibit
New Agreement
Other Events
Regulated Disclosure July 2022
Financial Exhibit
Regulated Disclosure June 2022
Bylaw Change
Financial Exhibit
New Agreement
Other Events
Security Holders Change June 2022
Other Events
August 2022
Event for Officers
Financial Exhibit
Regulated Disclosure
Financial Exhibit
Regulated Disclosure
August 2022
Earnings Release
Financial Exhibit
Financial Exhibit
August 2022
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
August 2022
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
July 2022
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
July 2022
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
July 2022
Financial Exhibit
New Agreement
Other Events
Regulated Disclosure
New Agreement
Other Events
Regulated Disclosure
July 2022
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
June 2022
Bylaw Change
Financial Exhibit
New Agreement
Other Events
Security Holders Change
Financial Exhibit
New Agreement
Other Events
Security Holders Change
June 2022
ZYME Merger Prospectus
425 Merger Prospectus July 2022
425 Merger Prospectus July 2022
425 Merger Prospectus July 2022
425 Merger Prospectus July 2022
425 Merger Prospectus July 2022
425 Merger Prospectus July 2022
425 Merger Prospectus July 2022
425 Merger Prospectus July 2022
425 Merger Prospectus July 2022
425 Merger Prospectus July 2022
425 Merger Prospectus July 2022
425 Merger Prospectus July 2022
425 Merger Prospectus July 2022
425 Merger Prospectus July 2022
425 Merger Prospectus July 2022
425 Merger Prospectus July 2022
425 Merger Prospectus July 2022
425 Merger Prospectus July 2022
425 Merger Prospectus July 2022
425 Merger Prospectus July 2022
Last10K.com | 10-K Annual Report Wed Mar 06 2019
Document and Entity Information - USD ($) $ in Millions | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2018 | Mar. 05, 2019 | Jun. 30, 2018 | |
| Document And Entity Information [Abstract] | |||
| Document Type | 10-K | ||
| Amendment Flag | false | ||
| Document Period End Date | Dec. 31, 2018 | ||
| Document Fiscal Year Focus | 2018 | ||
| Document Fiscal Period Focus | FY | ||
| Trading Symbol | ZYME | ||
| Entity Registrant Name | Zymeworks Inc. | ||
| Entity Central Index Key | 0001403752 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Voluntary Filers | No | ||
| Entity Filer Category | Accelerated Filer | ||
| Entity Shell Company | false | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | true | ||
| Entity Ex Transition Period | true | ||
| Entity Common Stock, Shares Outstanding | 32,025,299 | ||
| Entity Public Float | $ 406.9 |
View differences made from one year to another to evaluate Zymeworks Inc.'s financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Zymeworks Inc..
Assess how Zymeworks Inc.'s management team is paid from their Annual Proxy
Zymeworks Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Changes In Redeemable Convertible Preferred Shares And Shareholders' Equity
Consolidated Statements Of Changes In Redeemable Convertible Preferred Shares And Shareholders' Equity (Parenthetical)
Consolidated Statements Of Loss And Comprehensive Loss
Acquisition Of Kairos
Acquisition Of Kairos (Tables)
Acquisition Of Kairos - Additional Information (Detail)
Acquisition Of Kairos - Summary Of Carrying Value Of Ipr&Amp;D, Net Of Impairment (Detail)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Additional Information (Detail)
Commitments And Contingencies - Future Minimum Lease Payments Under Non-Cancellable Operating Leases And Capital Leases (Detail)
Financial Instruments
Financial Instruments - Additional Information (Detail)
Government Grants And Credits
Government Grants And Credits (Tables)
Government Grants And Credits - Additional Information (Detail)
Government Grants And Credits - Component Of Government Grants And Credits (Detail)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Detail)
Income Taxes - Schedule Of Income Tax Expense (Recovery) (Detail)
Income Taxes - Schedule Of Income Tax Expense (Recovery) (Parenthetical) (Detail)
Income Taxes - Schedule Of Reconciliation Of Beginning And Ending Amounts Of Unrecognized Tax Benefits (Detail)
Income Taxes - Summary Of Expiry Details Of Investment Tax Credits, Non-Capital Losses And Net Operating Losses For Income Tax Purposes (Detail)
Income Taxes - Summary Of Significant Components Of Deferred Income Tax Assets And Liabilities (Detail)
Intangible Assets
Intangible Assets (Tables)
Intangible Assets - Additional Information (Detail)
Intangible Assets - Schedule Of Intangible Assets (Detail)
Liabilities
Liabilities (Tables)
Liabilities - Schedule Of Accounts Payable And Accrued Liabilities (Detail)
Liabilities - Schedule Of Other Current Liabilities (Detail)
Liabilities - Schedule Of Other Long-Term Liabilities (Detail)
Nature Of Operations
Nature Of Operations - Additional Information (Detail)
Property And Equipment
Property And Equipment (Tables)
Property And Equipment - Additional Information (Detail)
Property And Equipment - Components Of Property And Equipment (Detail)
Recent Accounting Pronouncements
Redeemable Convertible Class A Preferred Shares And Shareholders' Equity
Redeemable Convertible Class A Preferred Shares And Shareholders' Equity (Tables)
Redeemable Convertible Class A Preferred Shares, And Shareholders' Equity - Additional Information (Detail)
Redeemable Convertible Class A Preferred Shares, And Shareholders' Equity - Schedule Of Estimated Fair Value Of Stock Options Assumptions (Detail)
Redeemable Convertible Class A Preferred Shares, And Shareholders' Equity - Schedule Of Non-Vested Stock Option Activity (Detail)
Redeemable Convertible Class A Preferred Shares, And Shareholders' Equity - Schedule Of Stock-Based Compensation Expense For Equity Classified Instruments (Detail)
Redeemable Convertible Class A Preferred Shares, And Shareholders' Equity - Summary Of Range Of Stock Options Granted (Detail)
Redeemable Convertible Class A Preferred Shares, And Shareholders' Equity - Summary Of Stock Options Granted (Detail)
Research Collaboration And Licensing Agreements
Research Collaboration And Licensing Agreements (Tables)
Research, Collaboration And Licensing Agreements - Additional Information - Beigene (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Celgene (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Daiichi Sankyo (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Daiichi Sankyo Two (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Gsk (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Gsk Two (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Janssen (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Leo (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Lilly (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Lilly Two (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Merck (Detail)
Research, Collaboration And Licensing Agreements - Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions (Detail)
Short-Term Investments
Short-Term Investments - Additional Information (Detail)
Subsequent Events
Subsequent Events - Additional Information (Detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Additional Information (Detail)
Summary Of Significant Accounting Policies - Schedule Of Changes In Fair Value Of Liability Classified Stock Options (Detail)
Summary Of Significant Accounting Policies - Schedule Of Changes In Fair Value Of Warrant Liabilities (Detail)
Summary Of Significant Accounting Policies - Schedule Of Financial Liabilities Measured At Fair Value On A Recurring Basis (Detail)
Summary Of Significant Accounting Policies - Summary Of Calculation Of Diluted Loss Per Share (Detail)
Summary Of Significant Accounting Policies - Summary Of Changes In Fair Value Of The Company's Liability For Contingent Consideration (Detail)
Summary Of Significant Accounting Policies - Summary Of Estimated Useful Lives (Detail)
Warrant Liabilities And Long-Term Debt
Warrant Liabilities And Long-Term Debt (Tables)
Warrant Liabilities And Long-Term Debt - Perceptive Debt - Additional Information (Detail)
Warrant Liabilities And Long-Term Debt - Summary Of Assumptions Used In Estimating Fair Value Of Warrants Determined Using Black-Scholes Option Pricing Model (Detail)
Warrant Liabilities And Long-Term Debt - Summary Of Debt (Detail)
Warrant Liabilities And Long-Term Debt - Warrant Liabilities - Additional Information (Detail)
Material Contracts, Statements, Certifications & more
Zymeworks Inc. provided additional information to their SEC Filing as exhibits
Exhibit 10.29: Material Contract
Exhibit 10.30: Material Contract
Exhibit 23.1: Consents Of Experts And Counsel
Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32.1: Section 1350 Certification
Exhibit 32.2: Section 1350 Certification
Exhibit 99.1: Additional Exhibits
Exhibit 99.2: Additional Exhibits
Exhibit 99.3: Additional Exhibits
Ticker: ZYME
CIK: 1403752
Form Type: 10-K Annual Report
Accession Number: 0001193125-19-065609
Submitted to the SEC: Wed Mar 06 2019 4:20:38 PM EST
Accepted by the SEC: Wed Mar 06 2019
Period: Monday, December 31, 2018
Industry: Pharmaceutical Preparations
External Resources:
Stock Quote
Social Media
Bookmark the Permalink: https://last10k.com/sec-filings/zyme/0001193125-19-065609.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...